AURA (Aura Biosciences) Days Sales Outstanding : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Days Sales Outstanding?

Aura Biosciences's average Accounts Receivable for the three months ended in Sep. 2024 was $0.00 Mil. Aura Biosciences's Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Aura Biosciences's Days Sales Outstanding or its related term are showing as below:

AURA's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 70.75
* Ranked among companies with meaningful Days Sales Outstanding only.

Aura Biosciences's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Aura Biosciences Days Sales Outstanding Historical Data

The historical data trend for Aura Biosciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences Days Sales Outstanding Chart

Aura Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Aura Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Aura Biosciences's Days Sales Outstanding

For the Biotechnology subindustry, Aura Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Days Sales Outstanding falls into.

Aura Biosciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Aura Biosciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Aura Biosciences's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Aura Biosciences (NAS:AURA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Aura Biosciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Boston, MA, USA, 02135

Website

https://www.aurabiosciences.com

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Executives

Janet Jill Hopkins	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
De Los Pinos Elisabet	director, officer: Chief Executive Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Julie B Feder	officer: Chief Financial Officer	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Matrix Capital Management Company, Lp	10 percent owner	1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cadmus Rich	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De	officer: Chief Operating Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp	10 percent owner	C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi	director	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel	10 percent owner	C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar	director	C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730